摘要
目的探讨非小细胞肺癌(NSCLC)患者血清Dickkopf-1(DKK-1)水平及其临床意义。方法采用夹心酶联免疫吸附法(ELISA)法测定102例NSCLC患者和40例肺部良性肺部疾病患者血清DKK-1水平,并以35例正常人血清作为对照,分析DKK-1与肺癌临床特征及预后的关系。结果 NSCLC患者血清DKK-1水平明显高于良性肺部疾病患者和正常对照组(P<0.01),以19.8 ng/ml为临界值,DKK-1对NSCLC诊断灵敏度为84.3%,特异度为80.3%。TNM分期Ⅲ-Ⅳ期患者血清DKK-1水平明显高于Ⅰ-Ⅱ期患者(P<0.01);有淋巴结转移患者高于无淋巴结转移的患者(P<0.01);手术前患者高于手术后患者(P<0.01);复发后病人明显高于复发前患者(P<0.01);存活期3年以上病人明显低于存活期3年以内病人(P<0.01)。结论血清DKK-1水平能够反映疾病的严重程度,可用于判定手术效果、监测复发和评估预后。
Objective To explore the levels and clinical significance of Dickkopf-1 ( DKK-1 ) in serum of patients with non-small cell lung cancer (NSCLC). Methods DKK-I levels of 102 cases of NSCLC, 40 eases of benign lung disease and 35 eases of healthy control were measured by sandwich enzyme linked immunosorbent assay (ELISA). Results The levels of NSCLC group were significantly higher than those of benign lung disease and healthy control groups ( P 〈 0.01 ) , when the cut-off value was 19.8 ng/ml, and the sensitiv- ity and specificity of NSCLC diagnosis were 84.3% and 80.3% respectively. The serum DKK-1 levels of m-lV stage NSCLC patients, with lymph node metastasis, before operation patients, recrudeseent patients and survival below 3 years patients were relatively higher than those in the I - ]I stage, without lymph node metastasis, after operation, no recrudescent and survival over 3 years patients respectively. There were significant differences ( P 〈 0.01 ). Conclusions DKK-1 level reflects the severity of the disease, and can also be used to de- termine effects of surgery, monitoring recurrence and evaluation of prognosis.
出处
《临床肺科杂志》
2012年第11期2044-2045,共2页
Journal of Clinical Pulmonary Medicine